Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (131-140 of 235) with videos related to

Pageof 24
Sort By:
Neoplasia (New York, N.Y.)|March 10, 2015
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcomeJoyce N Barlin, Qin C Zhou, Mario M Leitao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
The Spine Journal : Official Journal of the North American Spine Society|September 2, 2015
Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastasesDaniel E Spratt, Julio Arevalo-Perez, Jonathan E Leeman, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
JCO Oncology Practice|February 14, 2024
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task ForceManali I Patel, Leslie Hinyard, Janette K Merrill, et al.
Annals of Surgery|April 5, 2019
Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib ErasMichael J Cavnar, Kenneth Seier, Christina Curtin, et al.
Annals of Surgical Oncology|October 24, 2017
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic OutcomeMichael J Cavnar, Lin Wang, Vinod P Balachandran, et al.
Cancer Research Communications|March 17, 2023
Distinct IDH1/2-associated Methylation Profile and Enrichment of <i>TP53</i> and <i>TERT</i> Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional ChondrosarcomaJosephine Kam Tai Dermawan, Khedoujia Nafa, Abhinita Mohanty, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
Pageof 24

Showing results (131-140 of 235) with videos related to

Sort By:
Pageof 24
Neoplasia (New York, N.Y.)|March 10, 2015
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcomeJoyce N Barlin, Qin C Zhou, Mario M Leitao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
The Spine Journal : Official Journal of the North American Spine Society|September 2, 2015
Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastasesDaniel E Spratt, Julio Arevalo-Perez, Jonathan E Leeman, et al.
Investigational New Drugs|April 28, 2019
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumorsBin Fan, Ingo K Mellinghoff, Patrick Y Wen, et al.
JCO Oncology Practice|February 14, 2024
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task ForceManali I Patel, Leslie Hinyard, Janette K Merrill, et al.
Annals of Surgery|April 5, 2019
Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib ErasMichael J Cavnar, Kenneth Seier, Christina Curtin, et al.
Annals of Surgical Oncology|October 24, 2017
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic OutcomeMichael J Cavnar, Lin Wang, Vinod P Balachandran, et al.
Cancer Research Communications|March 17, 2023
Distinct IDH1/2-associated Methylation Profile and Enrichment of <i>TP53</i> and <i>TERT</i> Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional ChondrosarcomaJosephine Kam Tai Dermawan, Khedoujia Nafa, Abhinita Mohanty, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
ESMO Open|March 21, 2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcomaO O Babatunde, K Seier, G Schwartz, et al.
Pageof 24